Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024.

Revenue
+1,014.7%
EPS
+410.7%
Free cash flow
+49.8%
Total debt
−40.0%

Quarter to June 2026, against a year earlier

7.56 0.30 −3.82%
Market cap
$513.9M
P/E
39.5×
Fwd P/E
−786×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
37.28 65.53 195.68 290.88 703.10 1,552.50 1,240.20 1,280.20 1,067.30 700.70
Total non-current assets
0.65 1.32 3.60 10.76 14.30 29.10 28.60 24.40 24.10 17.20
Total Assets
37.94 66.85 199.28 301.64 717.40 1,581.60 1,268.80 1,304.60 1,091.40 717.90
Total current liabilities
10.03 17.85 22.98 32.81 49.20 261.70 295.10 257.10 229.80 142.50
Total non-current liabilities
3.87 48.75 39.63 42.14 26.00 538.20 408.80 387.50 299.90 141.50
Total liabilities
13.91 66.60 62.61 74.96 75.20 799.90 703.90 644.60 529.70 284.00
Common Equity (Total)
(32.88) (61.23) 136.67 226.69 642.20 781.70 564.90 660.00 561.70 433.90
Shareholders Equity (Total)
24.03 0.25 136.67 226.69 642.20 781.70 564.90 660.00 561.70 433.90
Total Debt
0.45 0.31 2.15 2.00 2.00 1.00 1.00 0.80 0.60 0.40

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026